FDA Approves Factor XIa Inhibitor Asundexian for Secondary Stroke Prevention

10 Nov 2026 0 comments

The FDA has approved asundexian, the first factor XIa inhibitor indicated to reduce recurrent stroke after a noncardioembolic ischemic stroke or high-risk TIA, based on phase 3 OCEANIC-STROKE data.

Source: NeurologyLive Published 09 Nov 2026 Imported 10 Nov 2026 Relevancy: Not reviewed

Read the article

Comments

No comments yet.

Unrestricted

All comments are reviewed before being published. Most comments are approved unless they are clearly inappropriate or unsafe.

Comments

Leave a comment